ES2180729T3 - Tratamiento terapeutico combinado de las patologias hiperproliferantes. - Google Patents

Tratamiento terapeutico combinado de las patologias hiperproliferantes.

Info

Publication number
ES2180729T3
ES2180729T3 ES96901387T ES96901387T ES2180729T3 ES 2180729 T3 ES2180729 T3 ES 2180729T3 ES 96901387 T ES96901387 T ES 96901387T ES 96901387 T ES96901387 T ES 96901387T ES 2180729 T3 ES2180729 T3 ES 2180729T3
Authority
ES
Spain
Prior art keywords
hyperproliferant
pathologies
combined treatment
therapeutic combined
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96901387T
Other languages
English (en)
Inventor
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2180729T3 publication Critical patent/ES2180729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA ASOCIACION MEDICAMENTOSA DE UNO O VARIOS ACIDOS NUCLEICOS QUE INHIBEN AL MENOS PARCIALMENTE LAS VIAS DE SEÑALIZACION CELULARES ONCOGENICAS Y DE UN AGENTE TERAPEUTICO ANTICANCEROSO, PARA SU UTILIZACION SIMULTANEA, SEPARADA O EXTENDIDA EN EL TIEMPO EN EL TRATAMIENTO DE LAS PATOLOGIAS HIPERPROLIFERATIVAS.
ES96901387T 1995-01-17 1996-01-12 Tratamiento terapeutico combinado de las patologias hiperproliferantes. Expired - Lifetime ES2180729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
ES2180729T3 true ES2180729T3 (es) 2003-02-16

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96901387T Expired - Lifetime ES2180729T3 (es) 1995-01-17 1996-01-12 Tratamiento terapeutico combinado de las patologias hiperproliferantes.

Country Status (21)

Country Link
US (3) US6262032B1 (es)
EP (1) EP0800399B1 (es)
JP (3) JP4580469B2 (es)
KR (1) KR100385266B1 (es)
AT (1) ATE222109T1 (es)
AU (1) AU716364B2 (es)
BR (1) BR9606969A (es)
CA (1) CA2209771C (es)
CZ (1) CZ298710B6 (es)
DE (1) DE69622989T2 (es)
DK (1) DK0800399T3 (es)
ES (1) ES2180729T3 (es)
FI (1) FI119911B (es)
FR (1) FR2729295A1 (es)
HU (1) HU229484B1 (es)
MX (1) MX9704490A (es)
NO (1) NO325418B1 (es)
PT (1) PT800399E (es)
SI (1) SI0800399T1 (es)
SK (1) SK283989B6 (es)
WO (1) WO1996022101A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
DK1641820T3 (da) * 2003-06-30 2008-09-15 Univ Lausanne Fra RasGap afledt peptid til selektiv at dræbe kræftceller
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
WO2005061007A1 (ja) * 2003-12-24 2005-07-07 St. Marianna University School Of Medicine 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274482B2 (en) * 1986-03-28 2003-03-12 The Board Of Trustees Of The University Of Illinois Isolated dna sequences associated with multidrug resistance in human cells
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
EP0642343B1 (en) * 1992-05-28 2000-08-30 Xenova Limited Acridine carboxamides for the treatment of cancer
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
JP2008133291A (ja) 2008-06-12
NO973197D0 (no) 1997-07-09
FI119911B (fi) 2009-05-15
DE69622989T2 (de) 2002-12-05
JP2012036201A (ja) 2012-02-23
CZ226297A3 (en) 1997-10-15
FI973023L (fi) 1997-07-16
JP5031921B2 (ja) 2012-09-26
HUP9802423A3 (en) 2000-11-28
CA2209771A1 (fr) 1996-07-25
MX9704490A (es) 1997-10-31
US20040127437A1 (en) 2004-07-01
DE69622989D1 (de) 2002-09-19
PT800399E (pt) 2002-12-31
EP0800399A1 (fr) 1997-10-15
SK95797A3 (en) 1997-12-10
NO973197L (no) 1997-07-09
KR100385266B1 (ko) 2005-09-07
SI0800399T1 (en) 2002-12-31
US7884082B2 (en) 2011-02-08
FR2729295A1 (fr) 1996-07-19
SK283989B6 (sk) 2004-07-07
DK0800399T3 (da) 2002-12-02
WO1996022101A1 (fr) 1996-07-25
CA2209771C (fr) 2012-01-03
JPH10512559A (ja) 1998-12-02
EP0800399B1 (fr) 2002-08-14
BR9606969A (pt) 1997-11-04
FR2729295B1 (es) 1997-02-28
US6262032B1 (en) 2001-07-17
US20010021395A1 (en) 2001-09-13
CZ298710B6 (cs) 2008-01-02
NO325418B1 (no) 2008-04-21
ATE222109T1 (de) 2002-08-15
HUP9802423A2 (hu) 1999-02-01
HU229484B1 (en) 2014-01-28
US20050209177A9 (en) 2005-09-22
FI973023A0 (fi) 1997-07-16
AU716364B2 (en) 2000-02-24
JP4580469B2 (ja) 2010-11-10
KR19980701449A (ko) 1998-05-15
AU4542996A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
GT199800126A (es) Terapia de combinacion.
MXPA02011303A (es) Nueva composicion farmaceutica.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2137372T3 (es) Solucion antifungica para las uñas.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
PT847757E (pt) Medicamento que compreende o gene de hgf
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
HN1999000045A (es) Derivados biciclicos del acido hidroxamico
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
AR012193A1 (es) Nuevas combinaciones terapeuticas
MX9704490A (es) Tratamiento terapeutico combinado de las patologias hiperproliferativas.
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ES2181710T3 (es) Adenovirus recombinantes y su utilizacion en terapia genica para el tratamiento de las patologias oculares.
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados